AstraZeneca and Ionis report Phase III success with eplontersen, a potential $3B drug.

AstraZeneca and Ionis have announced positive Phase III results for eplontersen, a drug for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a fatal neurodegenerative disease. Patients taking eplontersen recorded a 0.28-point average increase from baseline compared to a 25.06-point average increase in the placebo group. The drug is expected to generate over $3 billion in sales.